Document:

fusn-ex103_200.htm

 

Exhibit 10.3

Execution Copy

[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential.

Amendment. No. 2 to COLLABORATION AGREEMENT

This Amendment No. 2 ,  (this “Amendment”) dated as of July 27, 2021 (the “Effective Date”), to that certain Collaboration Agreement, dated as of December 10, 2020  and amended on June 28, 2021 (collectively, the “Agreement”), by and between, on the one hand, Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its registered offices at 270 Longwood Road S, Hamilton, Ontario L8P 0A6, Canada (“FPI”) and, on the other hand, TRIUMF Innovations Inc. (“TI”), a not-for-profit corporation continued under the Canada Not-for-profit Corporations Act, with its registered offices at 4004 Wesbrook Mall, Vancouver BC V6T 2A3, Canada and TRIUMF JV, a joint venture of The Governors of The University of Alberta, The University of British Columbia, The Governors of the University of Calgary, Carleton University, University of Guelph, University of Manitoba, McMaster University, Université de Montréal, Queen’s University, University of Regina, Simon Fraser University, The Governing Council of the University of Toronto, The University of Victoria and York University, and such other universities who have become or may become full members established pursuant to a contract governed by the laws of the Province of British Columbia, having its principal place of business at 4004 Wesbrook Mall, Vancouver BC V6T 2A3, Canada (collectively, TRIUMF Innovations Inc. and TRIUMF JV, “TRIUMF”).  Each of FPI, TI and TRIUMF JV may be referred to herein as a “Party” or together as the “Parties.”

BACKGROUND

WHEREAS, TRIUMF JV has transferred all of its assets and assigned all of its rights and obligations under the Agreement to its successor organization, TRIUMF INC. (the “Assignment”); and

WHEREAS, Section 14.5 (b) of the Agreement contemplates the Assignment and FPI has been provided with notification of such Assignment and provided its consent pursuant to the signed consent letter dated May 19, 2021; and  

WHEREAS, the Parties wish to amend the Agreement as set forth below. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1.Section 2.1(a)(v) of the Agreement is hereby deleted and the following is inserted in its place: “TRIUMF and FPI will negotiate and finalize the Phase 2 Collaboration Plan by no later than [***].  TRIUMF and FPI will negotiate and finalize the Phase 3 Framework on a timely basis, subject to, and following, the validation of the Ra-226 Production Process as provided in the Phase 2 Collaboration Plan. At the conclusion of Phase 1, TRIUMF will have full ownership of 

Ac-225 Manufactured during Phase 1 in excess of the quantity required to be provided to FPI in accordance with the Phase 1 Collaboration Plan and the Phase 1/2 Supply Agreement.”

2.All terms set forth in this Amendment shall have the definitions as set forth in the Agreement.

3.All other terms and conditions of the Agreement remain in full force and effect.

4.This Amendment may be executed in three (3) identical counterparts, each of which shall be deemed to be an original, and which collectively shall be deemed to be one (1) and the same instrument.  In addition, signatures may be exchanged by facsimile or PDF.

In Witness Whereof, the Parties have by duly authorized persons executed this Agreement as of the date first written above.

 

	
Fusion Pharmaceuticals Inc.
	
 
	
TRIUMF Innovations Inc.

	
 
	
 
	
 

	
Sign: /s/Maria Stahl
	
 
	
 
	
 
	
Sign: /s/Kathryn Hayashi
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Print Name: Maria Stahl
	
 
	
 
	
 
	
Print Name: Kathryn Hayashi
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Title: Chief Legal Officer
	
 
	
 
	
 
	
Title: President & CEO
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
TRIUMF INC.
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Sign: /s/Jim Hanlon
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Print Name: Jim Hanlon
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Title: Chief Administrative Officerfusn-ex104_199.htm

 

Exhibit 10.4

Execution Copy

[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential.

Amendment. No. 3 to COLLABORATION AGREEMENT

This Amendment No. 3 ,  (this “Amendment”) dated as of August 12, 2021 (the “Effective Date”), to that certain Collaboration Agreement, dated as of December 10, 2020  and amended on June 28, 2021 and July 27, 2021 (collectively, the “Agreement”), by and between, on the one hand, Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its registered offices at 270 Longwood Road S, Hamilton, Ontario L8P 0A6, Canada (“FPI”) and, on the other hand, TRIUMF Innovations Inc. (“TI”), a not-for-profit corporation continued under the Canada Not-for-profit Corporations Act, with its registered offices at 4004 Wesbrook Mall, Vancouver BC V6T 2A3, Canada and TRIUMF JV, a joint venture of The Governors of The University of Alberta, The University of British Columbia, The Governors of the University of Calgary, Carleton University, University of Guelph, University of Manitoba, McMaster University, Université de Montréal, Queen’s University, University of Regina, Simon Fraser University, The Governing Council of the University of Toronto, The University of Victoria and York University, and such other universities who have become or may become full members established pursuant to a contract governed by the laws of the Province of British Columbia, having its principal place of business at 4004 Wesbrook Mall, Vancouver BC V6T 2A3, Canada (collectively, TRIUMF Innovations Inc. and TRIUMF JV, “TRIUMF”).  Each of FPI, TI and TRIUMF JV may be referred to herein as a “Party” or together as the “Parties.”

BACKGROUND

WHEREAS, TRIUMF JV has transferred all of its assets and assigned all of its rights and obligations under the Agreement to its successor organization, TRIUMF INC. (the “Assignment”); and

WHEREAS, Section 14.5 (b) of the Agreement contemplates the Assignment and FPI has been provided with notification of such Assignment and provided its consent pursuant to the signed consent letter dated May 19, 2021; and  

WHEREAS, the Parties wish to amend the Agreement as set forth below. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1.The attached Exhibit E shall be added to the Agreement immediately after Exhibit D and any and all references to the “Phase 2 Collaboration Plan” in the Agreement shall be interpreted to mean Exhibit E. 

 

 
 

 

2.All terms set forth in this Amendment shall have the definitions as set forth in the Agreement.

3.All other terms and conditions of the Agreement remain in full force and effect.

4.This Amendment may be executed in three (3) identical counterparts, each of which shall be deemed to be an original, and which collectively shall be deemed to be one (1) and the same instrument.  In addition, signatures may be exchanged by facsimile or PDF.

In Witness Whereof, the Parties have by duly authorized persons executed this Agreement as of the date first written above.

 

	
Fusion Pharmaceuticals Inc.
	
 
	
TRIUMF Innovations Inc.

	
 
	
 
	
 

	
Sign: /s/Maria Stahl
	
 
	
 
	
 
	
Sign: /s/Kathryn Hayashi
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Print Name: Maria Stahl
	
 
	
 
	
 
	
Print Name: Kathryn Hayashi
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Title: Chief Legal Officer
	
 
	
 
	
 
	
Title: President & CEO
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
TRIUMF INC.
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Sign: /s/Jim Hanlon
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Print Name: Jim Hanlon
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Title: Chief Administrative Officer
	
 
	
 

 

 

 

 

Exhibit E to the Collaboration Agreement between FPI and TRIUMF

Phase II Collaboration Plan

 

[***]eighthamendment-federals

EIGHTH AMENDMENT  TO THE  FEDERAL SIGNAL CORPORATION SAVINGS RESTORATION PLAN  (As Amended and Restated Effective as of January 1, 2007)    WHEREAS, Federal Signal Corporation (the “Company”) maintains the Federal Signal  Corporation Savings Restoration Plan (the “Plan”); and  WHEREAS, the Plan has been amended, and further amendment of the Plan is now  considered desirable;   NOW, THEREFORE, IT IS RESOLVED that, pursuant to the power reserved to  the Benefits Planning Committee under Section 12 of the Plan, the Plan is hereby amended,  effective as of January 1, 2021, by substituting the following for subsection 9.1(c) of the Plan:  (c) Subsequent Elections to Change Form of Payment.  A Participant may, to  the extent permitted by the Committee in its sole discretion consistent with  Code Section 409A and any regulations thereunder, elect to further defer  the date when payment of any amount is to be made to a future date  specified by the Participant, provided that --  (i) the election is made more than 1 year prior to the date  payment of such amount is otherwise scheduled to begin;  (ii) the election does not become effective until at least 12  months after the election is made;  (iii) the date on which payment is to begin is delayed for at least  5 years from the date the payment would otherwise have  been made; and  (iv) the election meets such other requirements as may be  determined by the Committee to be necessary to comply  with Code Section 409A.  In the event payment has been elected by the Participant in the form of  installments, each installment payment shall be considered a separately  identifiable payment.  In the event payment has been elected by the  Participant in the form of a lump sum (or in the event payment shall be  made to the Participant in the form of a lump sum under the terms of the  Plan in the absence of or in lieu of the Participant’s election), then the  

 

 -2-   lump sum form shall be deemed to be a separately identifiable form of  payment.  Participants will be permitted to make such a change only once  with respect to any year’s Compensation Deferrals.  Explanation:  This amendment re-words subsection 9.1(c) of the Plan to clarify the meaning of  that subsection.  Subsection 9.1(c) permits participants to make a re-deferral election to defer  payment of some or a portion of their Plan accounts and choose to have that payment made to  them at a future date.  This amendment provides that a Participant may elect to have payments  made in a lump sum at a future date, in addition to the plan’s current practice of allowing re- deferral of payments to be made in installments to commence at a future date.    * * *    IN WITNESS WHEREOF, this Amendment has been executed by the Benefits Planning   Committee on behalf of the Company, this   4   day of        October       , 2021.        FEDERAL SIGNAL CORPORATION  BENEFITS PLANNING COMMITTEE               /s/ Shirley S. Paulson              .                   For the Benefits Planning Committee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]